Since ancient times, the PK of humans and diseases has never stopped, and medical care has always saved and protected human life. Nowadays, with the rapid development of biotechnology, bioinformatics and big data science are surging, and the “personalized†new generation of medical- precision medicine has made its debut!
On a sunny afternoon, at Predicine in Silicon Valley, the author interviewed Dr. Jia Shidong, a precision medical expert and founder and CEO of Predicine.
The dream of individualized medicine
The clock was reversed for 20 years. In the cold winter day in the north, Jia Shidong, an intern at Harbin Medical University, went to the doctor with the attending doctor. He saw dozens of patients in the morning of the respiratory department. The drugs were basically the same kind of drugs. Jia Shidong was strict. According to the teacher's guidance, symptomatic treatment, but in the subconscious, he felt that the same medicine could not have the same effect on everyone. The experience of that day led to his thinking: Can clinical treatment be treated differently for individual treatment, thus implementing individualized treatment? In this way, the dream of accurate diagnosis and personalized medicine has quietly sprouted in the heart of Jia Shidong. . .
Subsequently, Jia Shidong was admitted to the Chinese Medical Temple - Concord Medical University Ph.D., his research topic is the use of cutting-edge technology of molecular biology at that time, the cloning and sequencing of human papillomavirus genes associated with cervical cancer. After graduating from Ph.D., Jia Shidong went to the Dana-Farber Cancer Institute of Harvard Medical School for postdoctoral research. Here, he first discovered a new cancer drug target p110beta that can be used to treat a variety of cancers. This groundbreaking and important research was published in the world's top academic journal Nature in 2008, and he won the PART Researcher Award from the Dana-Farber Cancer Institute. The cancer drug target p110beta has triggered the development of new p110beta inhibitors by international pharmaceutical companies such as GSK and AstraZeneca, which are now in Phase I/Phase clinical trials worldwide.
In 2010, Dr. Jia Shidong joined the prestigious Novartis Institute for BioMedical Research, Inc. as the laboratory director, researching and developing CDK4/CDK6 inhibitors, which was recently approved by the US FDA for Treatment of advanced or metastatic breast cancer in postmenopausal women.
Subsequently, Dr. Jia Shidong came to Genentech, Calif., a model of the perfect combination of academic and pharmaceutical industry. As Director of the Laboratory and Head of the Tumor Precision Clinical Trial Program, he led and directly promoted the success of the AKT inhibitor drug in a phase II clinical trial of prostate cancer and breast cancer worldwide. Since 2014, Dr. Jia Shidong has also been the editor-in-chief of the Journal of Circulating Biomarkers, an academic journal, showing his strong research in cancer precision medicine and biomarker research!
Let the dream shine into reality
So, what prompted Dr. Jia Shidong to give up the superior working environment of Genentech and create Predicine?
First come to the brain to make up the human genetic material. We know that nucleic acids (DNA and RNA) are human genetic material, DNA forms RNA through transcription process, and RNA forms a functional protein through translation process. Variations in any part of DNA, RNA, and proteins can cause diseases, such as cancer.
Examination Glove,Nitrile Exam Gloves,Examination Gloves Price,Disposable Examination Gloves
Henan Anbang Medical Supplies Co., Ltd. , https://www.anbangmedical.com